drugset / Trial / NCT07473427

Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children

NCT07473427

Phase 3 Not yet recruiting 300 enrolled Sinovac (Dalian) Vaccine Technology Co., Ltd.
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This is a single armed, Phase 3 study to assess the immunogenicity and safety of the varicella vaccine manufactured by Sinovac. A total of 300 healthy participants aged 1-12 years will be enrolled. All participants will receive a single dose of varicella vaccine manufactured by Sinovac.

Timeline

Start
2026-06-15
Primary completion
2026-08-01
Completion
2026-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Varicella vaccine Vaccine

Indications